NuVasive (NUVA -13.8%) sells off after reporting Q3 revenue of $132.9M (+10.5% Y/Y) and EPS of $0.26; the latter beat by $0.03, but the former missed by $1.3M. In addition, NuVasive, which is mired in a costly legal battle with MDT, is guiding for 2011 revenue of $538M-$540M and EPS of $1.01-$1.02, below a consensus of $542M and $1.05.
NuVasive (NUVA -13.8%) sells off after reporting Q3 revenue of $132.9M (+10.5% Y/Y) and EPS of...
From other sites
at CNBC.com (Oct 4, 2012)
at CNBC.com (Oct 3, 2012)
at CNBC.com (Jun 28, 2012)
at CNBC.com (Jun 23, 2010)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs